Table 1 Demographic-, clinical and histopathological variables at baseline
From: “Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”
All frequency, n (%) | ROS1 IHC D4D6 Total: 891 Missing:30 | ROS1 IHC SP384 Total: 902 Missing 19 | |||
|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | ||
Total | 921 (100%) | 28 (3.1%) | 863 (96.9%) | 40 (4.4%) | 862 (95.6%) |
Age, median years (range) | 67.5 (39.2–87.0) | 67.8 (51.3–81.6) | 67.5 (39.2–87) | 68.4 (46.4–82.6) | 67.5 (39.2–87) |
Sex | |||||
Male | 474 (51.5%) | 13 (46.4%) | 447 (51.8%) | 19 (47.5%) | 444 (51.5%) |
Female | 447 (48.5%) | 15 (53.6%) | 416 (48.2%) | 21 (52.5%) | 418 (48.4%) |
Smoking status | |||||
Never smoker | 64 (6.9%) | 3 (10.7%) | 61(7.1%) | 11 (27.5%) | 53 (6.1%) |
Current/former smoker | 857 (93.1%) | 25 (89.3%) | 802 (92.9%) | 29 (72.5%) | 809 (93.9%) |
Median pack-year | 32.9 | 24 | 31.5 | 23.8 | 31.5 |
pStage | |||||
Ia and b | 501 (54.4%) | 17 (60.7%) | 463 (53.7%) | 26 (65%) | 462 (53.6%) |
IIa and b | 270 (29.3%) | 8 (28.6%) | 256 (29.7%) | 8 (20.0%) | 257 (29.8%) |
III a and b | 137 (14.9%) | 2 (7.1%) | 132 (15.3%) | 5 (12.5%) | 131 (15.2%) |
IV | 11 (1.2%) | 1 (3.6%) | 10 (1.2%) | 1 (2.5%) | 10 (1.2%) |
Unknown stage | 2 (0.2%) | 2 (0.2%) | 2 (0.2%) | ||
Histology | |||||
Adenocarcinoma (incl. former bronchioalveolar carc.) | 542 (58.8%) | 27 (96.4%) | 495 (57.4%) | 37 (92.5%) | 492 (57.1%) |
Adenosquamous | 16 (1.7%) | 0 | 16 (1.9%) | 0 | 16 (1.9%) |
Large cell carcinoma | 28 (3.0%) | 0 | 27 (3.1%) | 0 | 27 (3.1%) |
Squamous cell carcinoma | 300 (32.6%) | 0 | 291 (33.7%) | 3 (7.5%) | 292 (33.9%) |
Other | 35 (3.8%) | 1 (3.6%) | 34 (3.9%) | 0 | 35 (4.1%) |